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 We determined the natural history of IgA nephropathy 
(IgAN) among patients who presented with proteinuria, and 
factors associated with the development of clinical events,
namely　 blood　 pressure(BP)≧130/85　 mmHg,　 serum　 creatinine
≧1.4mg/dl.　 We　 analyzed　 data　 from　 16　 patients(mean　 age
35 ± 14 years) with IgAN accompanied by proteinuria be-
tween 1990 and 1998. We also semiquantified scores of 
glomerulosclerosis (GS), tubulointerstitial damage (TID), hya-
line arteriosclerosis (HA), and IgAN classification. The me-
dian duration of follow-up was 48 months. During clinical 
follow-up, seven (44%) patients became hypertensive, among 
who five (31%) developed impaired renal function and two 
(13%) progressed to treatment with hemodialysis. Events did 
not develop in the other 9 patients (56%). Clinical findings 
were not significantly different between the events and 
event-free groups. The GS and TID scores revealed signifi-
cant differences between patient groups. Only the renal 
histological parameters of GS and events were statistically 
correlated with renal survival. We conclude that the sever-
ity of GS may be the important prognostic factor inpatients 
with IgAN accompanied by proteinuria at the time of the 
initial biopsy. 
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dicting the long-term prognosis and more precisely, the 
subsequent development of ESRD, at the time of diagno-
sis remains difficult. Studies have shown that 
arterialthat arterial hypertension, proteinuria of over 1 g 
per day and the severity of histological lesions on initial 
renal biopsy specimens are risk factors that predict 
impairedpredict impaired renal function'- 12'. And hyper-
tension is a well-documented risk factor for the progres-
sion of IgAN13,141. Furthermore, many clinical studies 
have provided evidence that antihypertensive therapy 
prevents the progression of renal insufficiency"-"'. The 
purpose of the present study is to determine the IgAN 
among patients who presented with proteinuria less 
than 1 g per day, and clinical events such as hyper-
tension, renal function, and pathological data at initial 





 IgA nephropathy (IgAN) is the most prevalent type of 
primary glomerulonephritis worldwide and in Japan'-'). 
The natural history of the disease remains controversial, 
but the incidence of end-stage renal disease (ESRD), 
whether mild, moderate, or severe, ranges from 30% to 
40% within 20 years of evaluation"). However, pre-
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 We reviewed all patients who were diagnosed with 
IgAN from biopsy specimens at Nagasaki Municipal 
Medical Center (Nagasaki, Japan) during the period 
from 1990 to 1998. Patients with systemic diseases 
such as diabetes, lupus erythematosus, chronic liver dis-
eases, renal allografts and Henoch-Schonlein purpura 
were excluded. Patients were selected when the serum 
creatinine level below was 1.3 mg/dl, estimated 24-hour 
urinary creatinine clearance by the Gault-Cockroft 
equation"' was over 90m1/min per 1.73m2 body surface 
area, proteinuria was 0.5 to 1.0 g per day and signs of 
hypertension at the time of the initial renal biopsy 
were absent. At least 6 glomeruli19', 5 mm of cortex, 
and three arterioles were required in light microscopic 
sections. We analyzed records from 110 patients and 
selected 16 patients who met these criteria with a mini-
mum of 12 months of outpatient follow-up according to 
age, sex, follow-up period, serial serum creatinine levels, 
proteinuria, blood pressure and renal outcome.
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 We reviewed the clinical records of these 16 pa-
tients. Clinical follow-up and events included the de-
velopment of hypertension, (systolic blood pressure of 
>_ 130 mmHg or diastolic blood pressure of > 85 mmHg) 
and a need for antihypertensive therapy, defined as 
impaired renal function when serum creatinine levels 
increased to 1.4 mg/dl or greater, or an estimated 24-
hour urinary creatinine clearance of < 70 ml/min per 
1.73 m2 of body surface.
Morphologic examination
 Mesangial proliferation and the degree of sclerosis 
and/or hyalinosis of arterioles and interlobular arteries 
were evaluated using semiquantitative methods in all 
renal biopsy specimens. The percentage of sclerosed 
glomeruli was also determined. The degree of mesangial 
proliferation was determined for each glomerulus using 
a 5 grades according to the method by previous 
reported"). Histologic subclassification of IgAN: Grade 
1, minor change; Grade 2, segmental mild proliferation; 
Grade 3, segmental moderate or global mild prolifera-
tion; Grade 4, global moderate proliferation and Grade 
5, global severe proliferation. The grade was calculated 
as the mean value for the degree of mesangial prolif-
eration for all glomeruli evaluated. The score of 
glomerulosclerosis (GS) was defined as the percentage 
of sclerotic glomeruli divided by the total number of 
glomeruli: 0, none; 1, sclerosis of 25% or less; 2, sclero-
sis of 26% to 50%; 3, sclerosis of 51% to 75%; 4, sclero-
sis of 76% to 100%21). Tubulointerstitial damage (TID). 
Areas of tubular atrophy and interstitial fibrosis in 
the renal cortex, regardless of inflammatory cells, 
were estimated as ratios (%) and graded as follows: 
Grade 0, tubular atrophy and interstitial fibrosis were
Figure 1. Photomicrograph showing global severe mesangial 
proliferation, global glomerulosclerosis, tubular atrophy and, 
interstitial fibrosis (Periodic acid-Schiff; original magnifica-
tion x 120).
absent or less than 5%; 1, 5% to 49%; and 2, 50% or 
greater 22). Hyaline arteriosclerosis (HA) was graded as 
1, present or 0, absent") (Figure 1).
Statistics
 All data were statistically analyzed using Statview 
5.0 software for Windows (SAS Institute Inc., Cary, 
USA). Results are expressed as means ± SD unless 
otherwise stated. Statistical significance was examined 
using the Mann-Whitney U test with the Bonferroni 
correction. The incidence of adverse events was esti-
mated using the Kaplan-Meier method and compared 
using the log rank test. Multivariate analysis was not 
performed because of the relatively small number of 
selected patients. Variables included age at presenta-
tion, sex, serum IgA level, presence of macroscopic 
hematuria, proteinuria, and histologic grade of the 
renal biopsy specimen. A P value below 0.05 was con-
sidered statistically significant.
Results
 The mean age of the 7 male and 9 female patients 
at presentation was 35 ± 14 years (range 16 to 62). 
At presentation, 3 patients (18%) had elevated serum 
IgA concentrations (110 to 410 mg/dl) and none of 
the 16 had low serum complement levels. The median 
follow-up period was 48 months (range 12 to 124). 
During the follow-up in 16 IgAN, 7 patients (44%) be-
came hypertensive: renal function became impaired in 
5 (31%) of these and 2 (13%) progressed a need for 
hemodialysis 27 and 84 months after initial presenta-
tion (events group). Impaired renal function and hy-
pertension developed within a median of 28 (range 3 
to 58) and 44 months (range 23 to 77), respectively 
(Figure 2). Another 9 patients (56%) had persistent ab-
normalities in urinalysis examinations, although events 
did not develop (event-free group). The clinical find-
ings were not significantly different between the two 
groups (Table 1). 
 We summarized pathological changes in renal bi-
opsy specimens from the 16 patients (Table 2). The 
Glomerulosclerosis (GS) and Tubulointerstitial damage 
(TID) scores were significantly different between the 
groups (P = 0.003 and P = 0.03, respectively), but the 
hyaline arteriosclerosis (HA) scores and classifications 
of IgAN were not. Only the renal histological parameters 
of GS and events were statistically correlated with 
renal survival (Figure 3).
Yoshio Horita et al : Prognosis of IgA Nephropathy with Proteinuria
Table 2. Comparison of histopathologic renal findings in pa-
tients with immunoglobulin A nephropathy who did and did 
not develop events
                              Events Event-free 
                           (n = 7) (n = 9) P value 
Classification of IgAN 3.3 ±0.7 3.1-1:1.0 0.86 
Glomerulosclerosis 1.4-±-0.5 0.3±0.5 0.003 
Tubulointerstitial damage 2.0±0.9 0.8±1.0 0.03 
Hyaline arteriosclerosis 0.6±0.5 0.2±0.4 0.16 
Value expressed as mean±SD. n: number of patients
Figure 2. Cumulative probabilities of follow-up and clinical 
events. The median follow-up was 48 months (range 12 to 
124). During follow-up of 16 patients with Immunoglobulin A 
nephropathy, 7 (44%) became hypertensive: 5 (31%) developed 
impaired renal function and 2 (13%) progressed hemodialysis 27 
and 84 months after initial presentation. Impaired renal func-
tion and hypertension developed within a median of 28 
(range 3 to 58) and 44 months (range 23 to 77), respectively.
Table 1. Clinical characteristics of groups at the time of pres-
entation that did and did not develop events during subse-
quent follow-up period
Discussion
                                    Events Event-free 
                             (n = 7) (n = 9) P value 
Age (years) 39±10 31±16 0.22 
Gender (M/F) 2/5 5/4 0.29 
Body mass index (kg/mm2) 21.6± 1.7 23.0±3.1 0.11 
Serum creatinine (mg/dl) 1.0-!-0.2 1.0±0.1 0.14 
Urine creatinine (mg/dl) 78±26 110±69 0.49 
Creatinine clearance (ml/min) 99.7±4.3 98.0±7.8 0.87 
Serum Immunoglobulon A (mg/dl) 399±101 313±150 0.12 
Fibrinogen 314±83 288±102 0.49 
Serum complement titer (U/ml) 38.2±4.9 40.0±7.5 0.95 
Uric acid (mg/dl) 6.7± 1.1 6.0± 1.8 0.31 
Macrohematu is 1/6 3/6 0.39 
Proteinuria (g/day) 1.5-!-0.6 1.0±0.6 0.08 
                            Value expressed as mean±SD. n: number of patients
Time (months from biopsy)
Figure 3. Renal survival rates of patients with immunoglobulin 
A nephropathy accompanied by proteinuria (> 0.5 g per day) 
assessed by the presence of glomerulosclerosis. Survival rates 
were significantly higher when severity of glomerulosclerosis 
was low (P < 0.01).
  We examined the natural history of IgAN among 
 patients who presented with proteinuria. Our findings 
 suggested that the incidence of hypertension and im-
 paired renal function continued to increase with time. 
 Osawa et al."' indicated that an optimal level of BP (< 
 120/80 mmHg) was better than an intermediate level 
of BP (120/80 _< BP < 140/90) in preventing the pro-
 gression of renal damage in patients with IgAN. 
 Kanno et al.24' produced evidence indicating that re-
 ducing BP confers protective renal effects in patients 
 with mild renal insufficiency accompanied by hyper-
 tension in IgAN. Recently, the Japanese Society of 
 Hypertension Guidelines for the Management of 
 Hypertension in 2000 for the Detection, Evaluation, 
 and Treatment of High Blood Pressure recommended 
 a target BP of < 130/85 mmHg for patients with renal 
 disease, and a BP of < 125/75 mmHg in patients with 
 >_ 1 g/day of proteinuria25'. Szeto et al.21' recently re-
 ported that IgAN with proteinuria is a progressive dis-
 ease and recommended life-long follow-up with regular 
 monitoring of blood pressure. 
  The present study found that the severity of 
 glomerulosclerosis and chronic tubulointerstitial dam-
 age significantly correlated with clinical events includ-
 ing subsequent proteinuria, hypertension and impaired 
 renal function. Only the renal histological parameters 
 of glomerulosclerosis and adverse events were statisti-
 cally correlated with renal survival. The presence of 
 glomerulosclerosis tends to suggest progression, which 
 in turn suggests that although the severity of 
 glomerulosclerosis is the only morphological parameter
 that independently correlates with renal survival in adult 
 patients with IgAN, information about tubulointerstitial 
 damage and hyaline arteriosclerosis may be useful when 
 the renal pathological characteristics of individual pa-
 tients are assessed in clinical practice","). Therefore, we 
 postulate that presence/absence of glomerulosclerosis
 may be predictable the prognosis of patients with
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IgAN accompanied by proteinuria. One of the major 
limitations is the complexity of a grading system re-
lated to the inclusion of both acute and chronic lesions. 
Thus, the potential importance of chronicity indices 
may be masked. The importance of chronic lesions and 
of assessing glomerular and tubulointerstitial damage in 
the appraisal of IgAN has been reported","'. We there-
fore exclusively focused on chronic irreversible lesions 
and used a chronicity-based histological grading system 
that assessed glomerulosclerosis, tubulointerstitial dam-
age and hyaline arteriosclerosis over a long-term 
follow-up. Although histological grading systems such 
as classification of IgAN2", tubular lesions, vascular le-
sions, IgA deposit typography, and crescents have 
been used to evaluate the prognosis o IgAN27'28'30' we 
believe that this scoring system is convenient, simple 
to understand as a prognosticator for patients with 
IgAN. Our methods to determine prognostic factor in 
IgAN will need evaluating in a larger patients with 
IgAN. 
 In conclusion, the severity of glomerulosclerosis may 
be predictable prognostic factor in patients with IgAN 
accompanied by proteinuria at the time of the initial 
biopsy.
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